Aspire Biopharma authorizes USD 10 million share buyback program

• Aspire Biopharma Holdings board authorized a USD 10 million common stock repurchase program, effective Sept. 9, 2026.
• Repurchases may be executed in open-market purchases or privately negotiated transactions, subject to market and regulatory conditions.
• Program has no expiration date; the board can suspend or terminate it at any time.
• Authorization cited roughly 1,500,000 common shares outstanding as of Sept. 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609090830ACCESSWRNAPR_____1218473) on September 09, 2026, and is solely responsible for the information contained therein.